Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Cobiprostone - Sucampo Pharmaceuticals

Drug Profile

Cobiprostone - Sucampo Pharmaceuticals

Alternative Names: RU-8811; SPI-8811

Latest Information Update: 06 Mar 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Sucampo Pharmaceuticals
  • Class Fatty acids; Small molecules
  • Mechanism of Action Chloride channel agonists; Ion channel modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cystic fibrosis
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Chronic obstructive pulmonary disease; Gastro-oesophageal reflux; Inflammatory bowel diseases; Non-alcoholic steatohepatitis; NSAID-induced ulcer; Portal hypertension; Stomatitis; Wounds

Most Recent Events

  • 13 Feb 2018 Sucampo Pharmaceuticals has been acquired by Mallinckrodt
  • 11 Jul 2016 Discontinued - Phase-I for Stomatitis (In volunteers) in Japan (PO)
  • 11 Jul 2016 Discontinued - Phase-II for NSAID-induced ulcer (Prevention) in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top